Cancer Vaccines: The Next Huge Market for Big Pharma Depends on No Cures for Cancer

Health Impact News Editor

The cancer industry is probably the most lucrative business in the United States. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research, such as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care are $125 billion, with a projected 39 percent increase to $173 billion by 2020. Can you think of any other industry with those kinds of numbers and that kind of expected growth?

There is just one obvious problem with viewing cancer (or any other disease) as a profitable market for drugs: the market value and growth potential is predicated on NOT finding a cure for the disease. If a cure for the disease were discovered, particularly a natural one that did not require the purchase of expensive pharmaceutical products, the market disappears. There would be a loss of huge expenditures in tax revenues and hundreds of billions of dollars in lost revenue from sales. Probably tens of thousands, if not hundreds of thousands, of people would be put out of work in the medical field.

To understand how the medical system views cancer as a profitable disease to invest in, consider this recent medical press release from Market Reports Online explaining the market potential for new cancer vaccines (I offer my comments in red):

Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. (Note the admission that current cancer products, a $100+ billion industry, are ineffective.) Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized.

With the approval of the expenditure prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. (Note that for a cancer drug market to exist, it needs “approval” by the government FDA first, so with the first “approval” of a cancer vaccine expenditure by the government, other companies can now jump into the market and create vaccines also, and even apply for funding from your tax dollars to develop those drugs.)

The vaccine market, specifically the cancer vaccine market, has remained resilient to the global economic crisis in contrast to many life science sectors, which were severely impacted. Owing to drying pipelines and increasing pressure from patent expirations, the big pharma companies recognized the vaccine market as a potential resource for investors. Cancer vaccines are known to earn a higher profit than the generic drugs, owing to the nature of the disease and the urgency in the demand for these vaccines. (Note that the motivation to develop cancer vaccines is higher profitability, as patents expire on previous drugs – efficacy of the drug is neither discussed nor considered. Why would it be? That would kill the market.)

The US cancer vaccine market was estimated to be worth USD 14 billion in 2012. The market is expected to witness an increase of 1.5 million people being diagnosed with cancer annually. With such a rapid increase in the incidence, the US cancer vaccine market is expected to grow at a CAGR of 10% to surpass USD 20 billion by 2018. The market for cancer vaccine is in its growth stage in the US and has great opportunities for entry. (Note that the opportunities for such explosive growth in the cancer vaccine market is predicated on the fact that they will not cure or decrease the rate of cancer – otherwise the market would shrink, not grow.)

Full Press Release is here.

What is not mentioned in this press release, is why the vaccine market is so lucrative in general. Unlike any other classification of pharmaceutical products, you cannot sue a pharmaceutical company for faulty vaccines, or injuries and deaths due to vaccines. That’s because in the 1980s, there were so many claims filed in court against pharmaceutical companies for injuries or deaths due to vaccines, that the drug manufacturers basically blackmailed Congress and told them that they would no longer be able to continue manufacturing vaccines if they did not have legal immunity from lawsuits. Congress obliged, passing legislation to prevent anyone from suing pharmaceutical companies for injuries or deaths due to vaccine products, and the Supreme Court upheld the law in 2011.

So this is the main reason why vaccines are such a lucrative market: the government has propped up the largest financial bubble of all time in vaccine products. For a further explanation on this actual financial bubble, see the expose written by Michael Belkin, a world-renown financial analyst, The Vaccine Bubble.

The pharmaceutical companies could never survive with their vaccine products in a truly free market. They need government protection to sell their products, and the government has done a wonderful job in helping them market these products, and the mainstream media has done their part as well by not reporting on the true effects these defective products are causing in people’s lives.

One award-winning journalist who has left the mainstream media so he could report the truth, is Ben Swann. He has produced an excellent video (Truth In Media: Vaccine Court and Autism Cover-up Exposed) explaining how the vaccine court works, and why stories of vaccine injuries and death never make into the mainstream media:

So now we are looking at the wedding of two incredibly lucrative markets finally coming together to produce the largest cash cow the pharmaceutical industry has ever seen: cancer treatment and vaccines.

As we have noted above, and as the press release on market watch admits, these products are predicated on cancer not being cured. A cancer cure cannot be marketed.

I chose to use the word “marketed” in the last sentence instead of “developed”, because many effective cancer treatments have already been developed. But these treatments are not FDA approved, so they are driven underground or outside the U.S. Many of them have gone south of the border into Mexico. For an excellent summary of alternative cancer therapies that work and have been attacked by the government, watch the video Cancer: The Forbidden Cures.

In current times, Dr. Burzynski has fought for years to get his documented effective cancer treatments approved in the U.S., but if he were successful he would become the first person to ever be granted a patent and approved cancer treatment outside of the pharmaceutical companies, and just think of how that would effect the market watch as described above for the cancer business. For more on Dr. Burzynski, see: Cancer Patients Die as FDA Restricts Dr. Burzynski’s Treatment.

An award-winning film was created about his treatments and here is a trailer:

As we have stated above, the U.S. pharmaceutical market cannot survive in a free market. The government has to prop it up, and the government even earns revenue from vaccine royalties such as the HPV vaccines. The only thing that can stop them is YOU, the consumer, while you still have a choice. Only healthy people will bring down the huge pharmaceutical industry – they must have sick people to survive. Just say “NO” to drugs and vaccines.

We Lost the War on Cancer – Review of Alternative Cancer Therapies

eBook
Retail : ~~$9⁹⁹~~
Now : $5⁹⁹

We have lost the war on cancer. At the beginning of the last century, one person in twenty would get cancer. In the 1940s it was one out of every sixteen people. In the 1970s it was one person out of ten. Today one person out of three gets cancer in the course of their life.

The cancer industry is probably the most prosperous business in the United States. In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research, such as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care are $125 billion, with a projected 39 percent increase to $173 billion by 2020.

The simple fact is that the cancer industry employs too many people and produces too much income to allow a cure to be found. All of the current research on cancer drugs is based on the premise that the cancer market will grow, not shrink.

John Thomas explains to us why the current cancer industry prospers while treating cancer, but cannot afford to cure it in Part I. In Part II, he surveys the various alternative cancer therapies that have been proven effective, but that are not approved by the FDA.